Cardiologists, cardiac surgeons and cardiology APPs all earned more in 2024 than 2023, according to a new survey. Compensation in private practices continues to be much lower than it is integrated practices. 

"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology,"  Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.

Stereotaxis and CardioFocus are collaborating on a new robotic pulsed field ablation system. After completing some initial research, the companies are now working toward the launch of a clinical trial. 

When patients require PCI and TAVR, performing them at the same time is associated with both short- and long-term benefits. 

Different subtypes of depression are association with specific cardiometabolic diseases, according to new data out of the Netherlands. 

The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.

TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.

When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device. 

Are too many low-risk patients with severe AS undergoing TAVR instead of SAVR? According to one group of clinicians, "a significant public health concern may be looming."

If familial hypercholesterolemia is not detected and treated early, it can lead to premature heart attacks and heart disease in young patients.

Using an Impella heart pump during high-risk PCI was linked to a reduced short-term mortality rate and an acceptable safety profile.

A slow but sure approach to governance can keep AI champions focused on improving patient care when—and even after—the technology builds unstoppable momentum seemingly of its own accord.

The division develops and manufactures knee and hip replacements, along with other surgical implants. J&J said it will separate DePuy within 18 to 24 months, at which point it will be the largest orthopedics company in the world.